After hosting investor meetings with management, JPMorgan analyst Lisa Gill says the recent pullback in shares of Diplomat Pharmacy provides a good entry point. The meetings were positive with management highlighting the growth opportunities in both the specialty and pharmacy benefit management businesses, Gill tells investors in a research note. Further, she viewed the company’s commentary as favorable around the potential impact of President Trump’s drug price blueprint. The analyst reiterates an Overweight rating on Diplomat Pharmacy with a $27 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.